These compounds likely reduce low-molecular-weight HA production through coordinated regulation of HAS2 and HYAL1 expression, thereby attenuating HA-CD44 signaling pathway activity and ultimately inhibiting tumor growth. This evidence concerns the gene HAS2 and neoplasm.